IS CHOLESTEROL-LOWERING AN ALTERNATIVE TO REVASCULARIZATION IN SOME PATIENTS WITH CORONARY-ARTERY DISEASE

被引：6

作者：

HAVRANEK, EP

机构：

[1] Section of Cardiology, Denver General Hospital

[2] Section of Cardiology, MC 0960, Denver General Hospital, Denver, CO 80204

来源：

ARCHIVES OF INTERNAL MEDICINE | 1995年 / 155卷 / 07期

关键词：

D O I：

10.1001/archinte.155.7.670

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cholesterol lowering has been shown to decrease the dimensions of atherosclerotic plaques in some patients with coronary artery disease. Because of this observation, there is growing discussion about whether or not cholesterol lowering might be used in place of revascularization. The available data suggest that cholesterol lowering in place of revascularization may be appropriate for patients with chronic stable angina, for patients who are asymptomatic but have provocable ischemia after myocardial infarction, and for patients at moderate risk for cardiac events as judged by exercise test or clinical variables. The available data do not justify changing current practices; further study is necessary.

引用

页码：670 / 675

页数：6

共 46 条

[1]

Ornish D., Brown S., Scherwitz L.W., Et al., Can lifestyle changes reverse coronary heart disease?, Lancet, 336, pp. 129-133, (1990)

[2]

Brown G., Albers J.J., Fisher L.D., Et al., Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apoliprotein B, N Engl J Med, 323, pp. 1289-1298, (1990)

[3]

Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., Havel R.J., Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens, JAMA, 264, pp. 3007-3012, (1990)

[4]

Watts G.F., Lewis B., Brunt J.N.H., Et al., Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS), Lancet, 339, pp. 563-569, (1992)

[5]

Blankenhorn D.H., Azen S.P., Kramsch D.M., Et al., Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS), Ann Intern Med, 119, pp. 969-976, (1993)

[6]

Waters D., Higginson L., Gladstone P., Et al., Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial, Circulation, 89, pp. 959-968, (1994)

[7]

Haskell W.L., Alderman E.L., Fair J.M., Et al., Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: The Stanford Coronary Risk Intervention Project (SCRIP), Circulation, 89, pp. 975-990, (1994)

[8]

Superko H.R., Krauss R.M., Coronary artery disease regression: Convincing evidence for the benefit of aggressive lipoprotein management, Circulation, 90, pp. 1056-1069, (1994)

[9]

Heistad D.D., Armstrong M.L., Sick vessel syndrome: Can atherosclerotic arteries recover?, Circulation, 89, pp. 2447-2450, (1994)

[10]

Brown B.G., Zhao X.Q., Sacco D.E., Albers J.J., Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease, Circulation, 87, pp. 1781-1791, (1993)

← 1 2 3 4 5 →